A novel bispecific antibody cancer drug developed by Bristol Myers Squibb has demonstrated extraordinary efficacy in a large Phase 3 clinical trial, achieving a 94% objective response rate in patients with relapsed or refractory multiple myeloma — with 71% of participants achieving complete remission, meaning no detectable cancer cells remained after treatment.
How It Works
The drug BMS-986354 is a bispecific T-cell engager — a molecule engineered to simultaneously bind to a protein on myeloma cells and a protein on the patient's own immune T-cells, forcing the immune cell to recognise and destroy the tumour cell.
Path to Approval
Bristol Myers Squibb has filed for accelerated approval with the FDA. If approved, the drug could reach patients within 12-18 months.
Comments (6)
Leave a comment
I respectfully disagree with the conclusion drawn in the final paragraph. The data supports a more cautious interpretation. But it's a stimulating read nonetheless.
First time commenting here. Found this via social media. Incredible journalism — going to read more from this author.
This is one of the most comprehensive pieces of journalism I've read this year. The depth of reporting here is remarkable — I especially appreciated the inclusion of dissenting voices rather than just the official narrative. More of this, please.
As someone who has worked in this sector for 15 years, I can say the reporting here is accurate and the implications are as serious as the article suggests. The question is whether policymakers will act before it's too late.
The article would benefit from including voices from the communities most directly affected, rather than primarily quoting experts and officials. The people on the ground often have a different and equally valid perspective.
The statistics cited here are genuinely alarming. I work in the field and can confirm the trends described match what we're seeing on the ground. Thank you for bringing this to a wider audience.
Fantastic reporting. I've subscribed to the newsletter specifically because of articles like this. Keep up the excellent work.